Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT28S46)

• DTT Name: Leukocyte surface antigen CD47 (CD47)
• Synonyms: Protein MER6; MER6; Integrinassociated protein; Integrin-associated protein; IAP; Antigenic surface determinant protein OA3
• Gene Name: CD47
• DTT Type: Clinical trial target; [1]
• BioChemical Class: Osteoclast fusion complex
• UniProt ID: CD47_HUMAN
• TTD ID: T97766
• Sequence:
  MWPLVAALLLGSACCGSAQLLFNKTKSVEFTFCNDTVVIPCFVTNMEAQNTTEVYVKWKF
  KGRDIYTFDGALNKSTVPTDFSSAKIEVSQLLKGDASLKMDKSDAVSHTGNYTCEVTELT
  REGETIIELKYRVVSWFSPNENILIVIFPIFAILLFWGQFGIKTLKYRSGGMDEKTIALL
  VAGLVITVIVIVGAILFVPGEYSLKNATGLGLIVTSTGILILLHYYVFSTAIGLTSFVIA
  ILVIQVIAYILAVVGLSLCIAACIPMHGPLLISGLSILALAQLLGLVYMKFVASNQKTIQ
  PPRKAVEEPLNAFKESKGMMNDE
• Function: Plays an important role in memory formation and synaptic plasticity in the hippocampus. Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection. Has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins.
• KEGG Pathway: ECM-receptor interaction (hsa04512)
• Reactome Pathway:
  Integrin cell surface interactions (R-HSA-216083)
  Signal regulatory protein family interactions (R-HSA-391160)
  Neutrophil degranulation (R-HSA-6798695)
  Cell surface interactions at the vascular wall (R-HSA-202733)

Molecular Interaction Atlas (MIA) of This DTT

16 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hu5F9-G4	DMBER0Q	Myelodysplastic syndrome	2A37	Phase 3	[2]
Evorpacept	DMJTX7Q	Gastric cancer	2B72	Phase 2/3	[3]
PF-07901801	DMEVYHR	Diffuse large B-cell lymphoma	2A81	Phase 2	[4]
ALX148	DMGQX0U	Myelodysplastic syndrome	2A37	Phase 1/2	[2]
AO-176	DMXU98C	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[5]
DSP-107	DM8K0PR	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[6]
CC-90002	DMK0QDO	Acute myeloid leukaemia	2A60	Phase 1	[7]
IBI188	DMXUJ1P	Myelodysplastic syndrome	2A37	Phase 1	[8]
IMC-002	DMWSI04	Lymphoma	2A80-2A86	Phase 1	[9]
PF-07257876	DM0E2SW	Non-small-cell lung cancer	2C25	Phase 1	[10]
SL-172154	DMN3D72	Ovarian cancer	2C73	Phase 1	[11]
TG-1801	DM3K4FY	B-cell lymphoma	2A86	Phase 1	[12]
TJC4	DMLUOVS	Lymphoma	2A80-2A86	Phase 1	[13]
TTI-621	DMDNPAV	Haematological malignancy	2B33.Y	Phase 1	[1]
TTI-622	DMOCQ4K	Lymphoma	2A80-2A86	Phase 1	[14]
ZL-1201	DMTNUA4	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2021 Dec;22(12):1740-1751.
• [4] ClinicalTrials.gov (NCT05626322) A PHASE 1b/2 STUDY OF PF-07901801, A CD47 BLOCKING AGENT, WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION. U.S.National Institutes of Health.
• [5] Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Mol Cancer Ther. 2020 Mar;19(3):835-846.
• [6] Clinical pipeline report, company report or official report of KAHR Medical.
• [7] National Cancer Institute Drug Dictionary (drug name CC 90002).
• [8] Clinical pipeline report, company report or official report of Innovent Biologics.
• [9] Clinical pipeline report, company report or official report of ImmuneOncia Therapeutics.
• [10] ClinicalTrials.gov (NCT04881045) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS. U.S.National Institutes of Health.
• [11] Clinical pipeline report, company report or official report of Shattuck Labs.
• [12] Clinical pipeline report, company report or official report of TG Theraputics.
• [13] Clinical pipeline report, company report or official report of I-MAB Biopharma.
• [14] Clinical pipeline report, company report or official report of Trillium Therapeutics.
• [15] Clinical pipeline report, company report or official report of ZAI Lab.